1999
DOI: 10.1055/s-0037-1614434
|View full text |Cite
|
Sign up to set email alerts
|

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

Abstract: SummaryThe in vivo antithrombotic activity of RPR120844, a novel synthetic coagulation factor Xa (fXa) inhibitor (Ki = 7 nM), was assessed by its ability to inhibit thrombus formation in a damaged segment of the rabbit jugular vein. Intravenous dose-response studies were performed and thrombus mass (TM), activated partial thromboplastin time (APTT), prothrombin time (PT), inhibition of ex vivo fXa activity and plasma drug levels (PDL) were determined. TM, measured at the end of a 50 min infusion, was significa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2000
2000
2006
2006

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 18 publications
(1 citation statement)
references
References 13 publications
(16 reference statements)
0
1
0
Order By: Relevance
“…Orally active pyrazole DPC423 attenuates electrically induced carotid artery thrombosis in rabbits (140). Isoxazolines and isoxazoles prevent A-V shuntthrombosis (141), while RPR120844 reduces venous thrombosis in rabbits (142).…”
Section: Anti-fxamentioning
confidence: 99%
“…Orally active pyrazole DPC423 attenuates electrically induced carotid artery thrombosis in rabbits (140). Isoxazolines and isoxazoles prevent A-V shuntthrombosis (141), while RPR120844 reduces venous thrombosis in rabbits (142).…”
Section: Anti-fxamentioning
confidence: 99%